Abiopharma

Bicycle Therapeutics (BCYC) Announces Clinical Trial Update Bicycle Therapeutics (BCYC) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: potential
• Diseases/Conditions: an end-t
• Clinical Stage: Phase 1, Phase 2
• Collaboration: the United Kingdom Nuclear Decommissioning Authority
  • targeting Nectin-4, a well-validated tumor antigen; BT5528
  • targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com. Forward Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995
  • expected in 1Q 2026